Beijing Tiantan Biological Products Corp Ltd

SHG:600161 China Biotechnology
Market Cap
$4.32 Billion
CN¥31.72 Billion CNY
Market Cap Rank
#4923 Global
#571 in China
Share Price
CN¥16.04
Change (1 day)
-0.43%
52-Week Range
CN¥15.58 - CN¥23.17
All Time High
CN¥74.24
Categories
Companies in China Biotechnology
About

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamin… Read more

Beijing Tiantan Biological Products Corp Ltd (600161) - Net Assets

Latest net assets as of September 2025: CN¥14.95 Billion CNY

Based on the latest financial reports, Beijing Tiantan Biological Products Corp Ltd (600161) has net assets worth CN¥14.95 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥16.55 Billion) and total liabilities (CN¥1.60 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥14.95 Billion
% of Total Assets 90.31%
Annual Growth Rate 20.86%
5-Year Change 140.98%
10-Year Change 549.89%
Growth Volatility 38.53

Beijing Tiantan Biological Products Corp Ltd - Net Assets Trend (1995–2024)

This chart illustrates how Beijing Tiantan Biological Products Corp Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Beijing Tiantan Biological Products Corp Ltd (1995–2024)

The table below shows the annual net assets of Beijing Tiantan Biological Products Corp Ltd from 1995 to 2024.

Year Net Assets Change
2024-12-31 CN¥14.53 Billion +13.95%
2023-12-31 CN¥12.75 Billion +12.31%
2022-12-31 CN¥11.36 Billion +10.61%
2021-12-31 CN¥10.27 Billion +70.24%
2020-12-31 CN¥6.03 Billion +16.49%
2019-12-31 CN¥5.18 Billion +19.11%
2018-12-31 CN¥4.35 Billion +36.51%
2017-12-31 CN¥3.18 Billion +30.45%
2016-12-31 CN¥2.44 Billion +9.15%
2015-12-31 CN¥2.24 Billion +0.84%
2014-12-31 CN¥2.22 Billion +1.90%
2013-12-31 CN¥2.18 Billion +22.46%
2012-12-31 CN¥1.78 Billion +22.89%
2011-12-31 CN¥1.45 Billion +26.62%
2010-12-31 CN¥1.14 Billion +20.34%
2009-12-31 CN¥949.13 Million +25.39%
2008-12-31 CN¥756.97 Million +4.33%
2007-12-31 CN¥725.57 Million +2.43%
2006-12-31 CN¥708.35 Million +5.87%
2005-12-31 CN¥669.09 Million +5.07%
2004-12-31 CN¥636.79 Million +6.18%
2003-12-31 CN¥599.70 Million +107.48%
2002-12-31 CN¥289.04 Million -0.22%
2001-12-31 CN¥289.68 Million +3.75%
2000-12-31 CN¥279.21 Million -0.16%
1999-12-31 CN¥279.67 Million +5.22%
1998-12-31 CN¥265.80 Million +187.76%
1997-12-31 CN¥92.37 Million +53.47%
1996-12-31 CN¥60.19 Million +0.86%
1995-12-31 CN¥59.67 Million --

Equity Component Analysis

This analysis shows how different components contribute to Beijing Tiantan Biological Products Corp Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 641051396000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥6.41 Billion 57.55%
Common Stock CN¥1.98 Billion 17.75%
Other Components CN¥2.75 Billion 24.70%
Total Equity CN¥11.14 Billion 100.00%

Beijing Tiantan Biological Products Corp Ltd Competitors by Market Cap

The table below lists competitors of Beijing Tiantan Biological Products Corp Ltd ranked by their market capitalization.

Company Market Cap
Krones AG
PINK:KRNNF
 		$2.04 Billion
Ping An Healthcare and Technology Company Limited
PINK:PIAHY
 		$2.04 Billion
Mitsubishi Materials Corporation
PINK:MIMTF
 		$2.04 Billion
Kagome Co., Ltd.
PINK:KGMEF
 		$2.04 Billion
Page Industries Limited
NSE:PAGEIND
 		$2.03 Billion
Hilton Grand Vacations Inc
NYSE:HGV
 		$2.03 Billion
Jiangsu Expressway Company Limited
PINK:JEXYF
 		$2.03 Billion
Tecan Group Ltd
PINK:TCHBF
 		$2.03 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Beijing Tiantan Biological Products Corp Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 9,822,579,168 to 11,138,704,354, a change of 1,316,125,186 (13.4%).
  • Net income of 1,549,164,835 contributed positively to equity growth.
  • Dividend payments of 247,171,431 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥1.55 Billion +13.91%
Dividends Paid CN¥247.17 Million -2.22%
Other Changes CN¥14.13 Million +0.13%
Total Change CN¥- 13.40%

Book Value vs Market Value Analysis

This analysis compares Beijing Tiantan Biological Products Corp Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.86x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 321.07x to 2.86x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.05 CN¥16.04 x
1996-12-31 CN¥0.05 CN¥16.04 x
1997-12-31 CN¥0.08 CN¥16.04 x
1998-12-31 CN¥0.22 CN¥16.04 x
1999-12-31 CN¥0.23 CN¥16.04 x
2000-12-31 CN¥0.23 CN¥16.04 x
2001-12-31 CN¥0.24 CN¥16.04 x
2002-12-31 CN¥0.24 CN¥16.04 x
2003-12-31 CN¥0.50 CN¥16.04 x
2004-12-31 CN¥0.53 CN¥16.04 x
2005-12-31 CN¥0.56 CN¥16.04 x
2006-12-31 CN¥0.45 CN¥16.04 x
2007-12-31 CN¥0.45 CN¥16.04 x
2008-12-31 CN¥0.45 CN¥16.04 x
2009-12-31 CN¥0.53 CN¥16.04 x
2010-12-31 CN¥0.70 CN¥16.04 x
2011-12-31 CN¥0.85 CN¥16.04 x
2012-12-31 CN¥1.03 CN¥16.04 x
2013-12-31 CN¥1.28 CN¥16.04 x
2014-12-31 CN¥1.29 CN¥16.04 x
2015-12-31 CN¥1.33 CN¥16.04 x
2016-12-31 CN¥1.45 CN¥16.04 x
2017-12-31 CN¥2.02 CN¥16.04 x
2018-12-31 CN¥2.25 CN¥16.04 x
2019-12-31 CN¥2.62 CN¥16.04 x
2020-12-31 CN¥3.00 CN¥16.04 x
2021-12-31 CN¥5.03 CN¥16.04 x
2022-12-31 CN¥5.34 CN¥16.04 x
2023-12-31 CN¥4.96 CN¥16.04 x
2024-12-31 CN¥5.61 CN¥16.04 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Beijing Tiantan Biological Products Corp Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 13.91%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 25.68%
  • • Asset Turnover: 0.38x
  • • Equity Multiplier: 1.42x
  • Recent ROE (13.91%) is below the historical average (16.71%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 50.63% 30.13% 0.80x 2.09x CN¥24.24 Million
1996 36.01% 28.27% 0.58x 2.21x CN¥15.66 Million
1997 24.90% 30.59% 0.48x 1.70x CN¥13.76 Million
1998 12.63% 31.70% 0.28x 1.42x CN¥7.00 Million
1999 15.46% 31.39% 0.31x 1.57x CN¥15.24 Million
2000 13.60% 27.56% 0.31x 1.60x CN¥10.05 Million
2001 11.88% 22.16% 0.33x 1.60x CN¥5.43 Million
2002 12.58% 18.18% 0.40x 1.75x CN¥7.45 Million
2003 7.21% 17.65% 0.32x 1.27x CN¥-16.69 Million
2004 7.47% 16.39% 0.38x 1.20x CN¥-16.09 Million
2005 10.32% 20.10% 0.40x 1.27x CN¥2.14 Million
2006 15.40% 24.42% 0.39x 1.62x CN¥35.44 Million
2007 16.16% 19.74% 0.48x 1.69x CN¥39.90 Million
2008 20.09% 19.54% 0.57x 1.80x CN¥66.97 Million
2009 26.50% 19.24% 0.51x 2.71x CN¥131.79 Million
2010 16.58% 14.55% 0.49x 2.32x CN¥69.43 Million
2011 18.10% 16.73% 0.43x 2.50x CN¥104.46 Million
2012 19.62% 20.30% 0.31x 3.09x CN¥149.51 Million
2013 19.32% 20.26% 0.33x 2.93x CN¥179.43 Million
2014 6.61% 7.03% 0.30x 3.10x CN¥-65.71 Million
2015 0.51% 0.62% 0.29x 2.90x CN¥-184.18 Million
2016 11.71% 12.01% 0.37x 2.64x CN¥37.44 Million
2017 38.59% 47.24% 0.68x 1.21x CN¥869.17 Million
2018 15.11% 17.38% 0.58x 1.50x CN¥172.35 Million
2019 15.51% 18.62% 0.52x 1.60x CN¥217.20 Million
2020 14.14% 18.55% 0.46x 1.67x CN¥187.21 Million
2021 9.44% 18.48% 0.36x 1.44x CN¥-45.19 Million
2022 10.02% 20.67% 0.33x 1.47x CN¥1.34 Million
2023 11.30% 21.42% 0.37x 1.44x CN¥127.63 Million
2024 13.91% 25.68% 0.38x 1.42x CN¥435.29 Million

Industry Comparison

This section compares Beijing Tiantan Biological Products Corp Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,043,310,248
  • Average return on equity (ROE) among peers: 14.20%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Beijing Tiantan Biological Products Corp Ltd (600161) CN¥14.95 Billion 50.63% 0.11x $2.03 Billion
Shenzhen CAU Technology Co Ltd (000004) $124.02 Million 4.50% 1.13x $80.66 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $525.49 Million 14.76% 1.41x $1.02 Billion
Nanhua Bio Medicine Co Ltd (000504) $174.34 Million 36.11% 1.61x $288.51 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $642.80 Million -4.58% 0.44x $244.62 Million
Chengzhi Shareholding Co Ltd (000990) $1.69 Billion 3.06% 0.97x $850.04 Million
Hualan Biological EngineeringInc (002007) $1.86 Billion 32.78% 0.08x $2.00 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $2.09 Billion 4.42% 0.71x $784.18 Million
Shanghai RAAS Blood Products Co Ltd Class A (002252) $831.21 Million 22.32% 0.12x $3.76 Billion
Baolingbao Biology Co Ltd (002286) $2.04 Billion 5.44% 0.31x $398.99 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $456.61 Million 23.20% 0.29x $347.95 Million